DE60102473T2 - Indolochinazolinone - Google Patents

Indolochinazolinone Download PDF

Info

Publication number
DE60102473T2
DE60102473T2 DE60102473T DE60102473T DE60102473T2 DE 60102473 T2 DE60102473 T2 DE 60102473T2 DE 60102473 T DE60102473 T DE 60102473T DE 60102473 T DE60102473 T DE 60102473T DE 60102473 T2 DE60102473 T2 DE 60102473T2
Authority
DE
Germany
Prior art keywords
alkyl
acid addition
free base
addition salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60102473T
Other languages
German (de)
English (en)
Other versions
DE60102473D1 (de
Inventor
Kaspar Zimmermann
Robert Portmann
Franklin Dean RIGEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60102473D1 publication Critical patent/DE60102473D1/de
Publication of DE60102473T2 publication Critical patent/DE60102473T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
DE60102473T 2000-07-17 2001-07-16 Indolochinazolinone Expired - Lifetime DE60102473T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0017508.3A GB0017508D0 (en) 2000-07-17 2000-07-17 Antimicrobials
GB0017508 2000-07-17
PCT/EP2001/008192 WO2002006284A1 (en) 2000-07-17 2001-07-16 Indoloquinazolinones

Publications (2)

Publication Number Publication Date
DE60102473D1 DE60102473D1 (de) 2004-04-29
DE60102473T2 true DE60102473T2 (de) 2005-02-03

Family

ID=9895801

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60102473T Expired - Lifetime DE60102473T2 (de) 2000-07-17 2001-07-16 Indolochinazolinone

Country Status (19)

Country Link
US (1) US6964960B2 (ja)
EP (1) EP1303517B1 (ja)
JP (1) JP3939246B2 (ja)
CN (1) CN1183136C (ja)
AR (1) AR031379A1 (ja)
AT (1) ATE262530T1 (ja)
AU (1) AU2001279754A1 (ja)
BR (1) BR0112521A (ja)
CA (1) CA2415683C (ja)
DE (1) DE60102473T2 (ja)
DK (1) DK1303517T3 (ja)
ES (1) ES2218439T3 (ja)
GB (1) GB0017508D0 (ja)
HK (2) HK1056872A1 (ja)
MY (1) MY133969A (ja)
PE (1) PE20020210A1 (ja)
PT (1) PT1303517E (ja)
TR (1) TR200401026T4 (ja)
WO (1) WO2002006284A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
JP2008531562A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
EP1937268A4 (en) 2005-08-24 2009-07-22 Inotek Pharmaceuticals Corp INDENOISOQUINOLINONE ANALOGUES AND METHODS OF USE
JP5284955B2 (ja) * 2006-06-20 2013-09-11 アボット・ラボラトリーズ Ｐａｒｐ阻害剤としてのピラゾロキナゾリノン
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
JP2010520220A (ja) 2007-02-28 2010-06-10 イノテック ファーマシューティカルズ コーポレイション インデノイソキノリノン類似体およびその使用方法
EP2409700A1 (en) 2007-05-08 2012-01-25 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
US9062061B2 (en) 2011-07-13 2015-06-23 Santen Pharmaceutical Co., Ltd. Compound having PARP inhibitory activity
CN102766144B (zh) * 2012-07-10 2014-04-23 浙江大学 一种吲哚并[1,2-c]喹唑啉化合物的制备方法
PT3325623T (pt) 2015-07-23 2019-09-04 Inst Curie Utilização de uma combinação de molécula dbait e de inibidores de parp para o tratamento do cancro
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
JP2021515580A (ja) 2018-03-13 2021-06-24 オンクセオＯｎｘｅｏ がんの治療における獲得耐性に対抗するｄｂａｉｔ分子
WO2020109524A1 (de) * 2018-11-30 2020-06-04 Merck Patent Gmbh Verbindungen für elektronische vorrichtungen
WO2020182779A1 (de) * 2019-03-12 2020-09-17 Merck Patent Gmbh Materialien für organische elektrolumineszenzvorrichtungen
CN110357892B (zh) * 2019-07-10 2022-06-07 云南大学 四氢嘧啶并[1,2-a]吲哚衍生物及其合成方法与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114195789B (zh) * 2021-12-15 2022-09-09 广东海洋大学 一种无金属参与的多环吲哚衍生物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635966A (en) 1969-10-22 1972-01-18 Robins Co Inc A H 6-substituted-indolo(1 2-c)quinazolines
DE2237372C3 (de) 1972-07-29 1981-07-09 Basf Ag, 6700 Ludwigshafen Heterocyclische Farbstoffe, ihre Herstellung und ihre Verwendung
US5441955A (en) 1993-11-19 1995-08-15 Pathogenesis Corporation Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues

Also Published As

Publication number Publication date
AU2001279754A1 (en) 2002-01-30
CA2415683A1 (en) 2002-01-24
JP2004504323A (ja) 2004-02-12
ES2218439T3 (es) 2004-11-16
ATE262530T1 (de) 2004-04-15
TR200401026T4 (tr) 2004-07-21
JP3939246B2 (ja) 2007-07-04
MY133969A (en) 2007-11-30
DK1303517T3 (da) 2004-06-21
BR0112521A (pt) 2003-07-01
GB0017508D0 (en) 2000-08-30
PE20020210A1 (es) 2002-04-04
HK1056872A1 (en) 2004-03-05
AR031379A1 (es) 2003-09-24
HK1055426A1 (en) 2004-01-09
CN1441803A (zh) 2003-09-10
US6964960B2 (en) 2005-11-15
CN1183136C (zh) 2005-01-05
EP1303517B1 (en) 2004-03-24
EP1303517A1 (en) 2003-04-23
DE60102473D1 (de) 2004-04-29
CA2415683C (en) 2009-12-29
WO2002006284A1 (en) 2002-01-24
US20030199502A1 (en) 2003-10-23
PT1303517E (pt) 2004-07-30

Similar Documents

Publication Publication Date Title
DE60102473T2 (de) Indolochinazolinone
EP0270947B1 (de) Substituierte basische 2-Aminotetraline
EP0589874B1 (de) Verwendung von (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure zur herstellung eines langzeitantidiabetikums
DE60202958T2 (de) Stabiles polymorph von flibanserin, industrielles verfahren zu dessen herstellung und dessen verwendung zur herstellung von medikamenten
EP0888313B1 (de) 2,3-benzodiazepinderivate und deren verwendung als ampa-rezeptoren-hemmer
DE2635516C3 (de) Neue Derivate des Thiazolo[3,4-b]isochinolins, ihre Herstellung und die sie enthaltenden Zusammensetzungen
DE2363052A1 (de) 3-phenyl-3-aminoalkyl-2,6-dioxo-tetraund -hexahydropyridine, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zubereitungen
DE69720021T2 (de) 1,4-disubstituierte piperazine
DE69818516T2 (de) Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
DE2505297A1 (de) Neue 2-arylamino-2-imidazolinderivate und ein verfahren zu deren herstellung
DE3334757A1 (de) Piperazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate
DE3149010A1 (de) (+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten
AT414125B (de) Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
DD272648A5 (de) Chromon-derivate
DD147110A5 (de) Verfahren zur herstellung von 9-eckige klammer auf 3-(3.5-cis-dimethylpiperazino)-propyl eckige klammer zu-carbazol und dessen salzen
EP0254955B1 (de) Substituierte Pyrido-[2,3-b][1,4]benzodiazepin-6-one, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2651789C2 (de) Purinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
DD208980A5 (de) Verfahren zur herstellung von hexahydro-trans- und tetrahydropyridoindolen
EP0312895A2 (de) Kondensierte Diazepinone, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69232980T2 (de) Pyrroloazepinderivate
DE2535599C2 (de) Substituierte Zimtsäureamide, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen, welche diese Verbindungen enthalten
EP0018360A1 (de) N-(5-Methoxybentofuran-2-ylcarbonyl)-N'-benzylpiperazin und Verfahren zu dessen Herstellung.
DE1076691B (de) Verfahren zur Herstellung von Phenthiazinderivaten
EP0266308A1 (de) Indolo-pyrazino-benzodiazepin-Derivate
EP0174459B1 (de) 9- beziehungsweise 11-(Nitro)-apovincaminsäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN